WO2003020711A1 - Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin - Google Patents

Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin Download PDF

Info

Publication number: WO2003020711A1
Authority: WO; WIPO (PCT)
Prior art keywords: skin; external preparations; compounds; matrix metalloprotease; metalloprotease inhibitors
Prior art date: 2001-08-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

PCT/JP2002/008649

Other languages

English (en)

French (fr)

Inventor

Takuya Hiruma

Koji Kobayashi

Shinji Inomata

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shiseido Co Ltd

Original Assignee

Shiseido Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-28

Filing date

2002-08-28

Publication date

2003-03-13

2002-08-28 Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd

2002-08-28 Priority to US10/487,411 priority Critical patent/US7348017B2/en

2002-08-28 Priority to DE60224203T priority patent/DE60224203T2/de

2002-08-28 Priority to EP02772819A priority patent/EP1422224B1/en

2002-08-28 Priority to KR1020047001888A priority patent/KR100911092B1/ko

2003-03-13 Publication of WO2003020711A1 publication Critical patent/WO2003020711A1/ja

2004-02-28 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Gerontology & Geriatric Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Birds (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Plural Heterocyclic Compounds (AREA)

PCT/JP2002/008649 2001-08-28 2002-08-28 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin Ceased WO2003020711A1 (en)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
US10/487,411 US7348017B2 (en)	2001-08-28	2002-08-28	Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
DE60224203T DE60224203T2 (de)	2001-08-28	2002-08-28	DITHIAZOLVERBINDUNGEN, MATRIX-METALLOPROTEASE-INHIBITOREN UND ZUBEREITUNGEN FÜR DIE ÄUßERLICHE ANWENDUNG AUF DER HAUT
EP02772819A EP1422224B1 (en)	2001-08-28	2002-08-28	Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
KR1020047001888A KR100911092B1 (ko)	2001-08-28	2002-08-28	디티아졸 화합물 및 매트릭스 메탈로프로테아제 활성저해제, 피부외용제

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001258066A JP4825375B2 (ja)	2001-08-28	2001-08-28	ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
JP2001-258066		2001-08-28

Publications (1)

Publication Number	Publication Date
WO2003020711A1 true WO2003020711A1 (en)	2003-03-13

Family

ID=19085645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/008649 Ceased WO2003020711A1 (en)	2001-08-28	2002-08-28	Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin

Country Status (7)

Country	Link
US (1)	US7348017B2 (ja)
EP (1)	EP1422224B1 (ja)
JP (1)	JP4825375B2 (ja)
KR (1)	KR100911092B1 (ja)
CN (1)	CN1319957C (ja)
DE (1)	DE60224203T2 (ja)
WO (1)	WO2003020711A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010016681A3 (en) *	2008-08-04	2010-06-03	Snu R&Db Foundation	Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of lxr-alpha
US20120064060A1 (en) *	2004-06-23	2012-03-15	Ono Pharmaceutical Co., Ltd.	Compound having s1p receptor binding potency and use thereof
WO2012049153A1 (en)	2010-10-12	2012-04-19	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRE20010042A1 (it) *	2001-04-24	2002-10-24	Corghi Spa	Dispositivo sollevatore per macchine smontagomme
BRPI0409469B1 (pt) *	2003-04-15	2016-04-26	Wellstat Therapeutics Corp	compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
WO2005097817A2 (en) *	2004-04-05	2005-10-20	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
AU2005310238A1 (en) *	2004-10-29	2006-06-08	Merck Sharp & Dohme Corp.	N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
WO2007030567A2 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	Pparactive compounds
US20090203851A1 (en) *	2006-06-02	2009-08-13	Dsm Ip Assets B.V.	Process for the Preparation of a Hydroxy-Aromatic Resin: Hydroxy-Aromatic Resin, and Modification Thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3753908A (en) *	1971-08-30	1973-08-21	Chevron Res	Oxidation inhibited lubricating oil compositions with extreme pressure properties
DE2228364A1 (de) *	1972-06-10	1973-12-20	Bergwerksverband Gmbh	Verfahren zur herstellung von 3-acylamino-1,2,4-dithiazolin-5-thionen (acylxanthanwasserstoffe)
WO1995019956A1 (en) *	1994-01-20	1995-07-27	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
WO1996040745A2 (en) *	1995-06-07	1996-12-19	Proscript, Inc.	Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases
WO1997040031A1 (en) *	1996-04-23	1997-10-30	Pharmacia & Upjohn Company	Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
WO1998054198A1 (en) *	1997-05-30	1998-12-03	Hybridon, Inc.	Novel sulfur transfer reagents for oligonucleotide synthesis
WO1999032111A1 (en) *	1997-12-22	1999-07-01	Bayer Corporation	INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1021424E (pt) *	1996-06-21	2003-06-30	Upjohn Co	Amidas de tiadiazolo como inibidores da metaloproteinase de matriz
NZ334256A (en)	1996-08-28	2000-11-24	Procter & Gamble	1-substituted sulphonyl-pyrrolidine derivatives useful as metalloprotease inhibitors

2001
- 2001-08-28 JP JP2001258066A patent/JP4825375B2/ja not_active Expired - Fee Related
2002
- 2002-08-28 DE DE60224203T patent/DE60224203T2/de not_active Expired - Lifetime
- 2002-08-28 CN CNB028171039A patent/CN1319957C/zh not_active Expired - Fee Related
- 2002-08-28 US US10/487,411 patent/US7348017B2/en not_active Expired - Fee Related
- 2002-08-28 KR KR1020047001888A patent/KR100911092B1/ko not_active Expired - Fee Related
- 2002-08-28 EP EP02772819A patent/EP1422224B1/en not_active Expired - Lifetime
- 2002-08-28 WO PCT/JP2002/008649 patent/WO2003020711A1/ja not_active Ceased

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3753908A (en) *	1971-08-30	1973-08-21	Chevron Res	Oxidation inhibited lubricating oil compositions with extreme pressure properties
DE2228364A1 (de) *	1972-06-10	1973-12-20	Bergwerksverband Gmbh	Verfahren zur herstellung von 3-acylamino-1,2,4-dithiazolin-5-thionen (acylxanthanwasserstoffe)
WO1995019956A1 (en) *	1994-01-20	1995-07-27	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
WO1996040745A2 (en) *	1995-06-07	1996-12-19	Proscript, Inc.	Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases
WO1997040031A1 (en) *	1996-04-23	1997-10-30	Pharmacia & Upjohn Company	Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
WO1998054198A1 (en) *	1997-05-30	1998-12-03	Hybridon, Inc.	Novel sulfur transfer reagents for oligonucleotide synthesis
WO1999032111A1 (en) *	1997-12-22	1999-07-01	Bayer Corporation	INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1422224A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120064060A1 (en) *	2004-06-23	2012-03-15	Ono Pharmaceutical Co., Ltd.	Compound having s1p receptor binding potency and use thereof
US8653305B2 (en) *	2004-06-23	2014-02-18	Ono Pharmaceutical Co., Ltd.	Compound having S1P receptor binding potency and use thereof
WO2010016681A3 (en) *	2008-08-04	2010-06-03	Snu R&Db Foundation	Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of lxr-alpha
US9370504B2 (en)	2008-08-04	2016-06-21	Snu R&Db Foundation	Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α
WO2012049153A1 (en)	2010-10-12	2012-04-19	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof

Also Published As

Publication number	Publication date
US20040236111A1 (en)	2004-11-25
CN1549809A (zh)	2004-11-24
EP1422224B1 (en)	2007-12-19
US7348017B2 (en)	2008-03-25
JP2003064065A (ja)	2003-03-05
CN1319957C (zh)	2007-06-06
KR20040032149A (ko)	2004-04-14
KR100911092B1 (ko)	2009-08-06
EP1422224A4 (en)	2005-11-09
DE60224203T2 (de)	2008-12-04
EP1422224A1 (en)	2004-05-26
DE60224203D1 (de)	2008-01-31
JP4825375B2 (ja)	2011-11-30

Publication	Publication Date	Title
NZ337298A (en)	2002-11-26	N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
PL370991A1 (en)	2005-06-13	New inhibitors of histone deacetylase
PL371100A1 (en)	2005-06-13	Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
PL370982A1 (en)	2005-06-13	Carbonylamino-derivatives as novel inhibitors of histone deacetylase
MXPA04007775A (es)	2004-10-15	Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
EP1396493A4 (en)	2005-08-03	HETEROCYCLIC COMPOUNDS
MXPA04008795A (es)	2004-11-26	Derivados de piperazinilo, piperidinilo y morfolino como novedosos inhibidores de la desacetilasa de histona.
TW200420542A (en)	2004-10-16	A compound having TGF β inhibition activity and a medicinal composition containing the same
WO2005061458A3 (en)	2005-10-13	Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP0931788A3 (en)	1999-08-04	Metalloprotease inhibitors
AU2002236830A1 (en)	2002-08-06	Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
NO20051695L (no)	2005-04-05	Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
WO2001085680A3 (en)	2002-03-07	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
CA2336412A1 (en)	2000-01-13	Medicament for treatment of diabetes
WO2003076417A3 (en)	2003-11-13	Oxo-azabicyclic compounds
WO2003020711A1 (en)	2003-03-13	Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
WO2004014868A8 (en)	2004-07-29	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2003016248A3 (en)	2003-10-23	Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
TW200616998A (en)	2006-06-01	Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase
WO2004108086A3 (en)	2005-03-31	HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
WO2003055856A3 (en)	2004-01-08	BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
WO2005058841A3 (en)	2006-03-09	Hiv protease inhibiting compounds
WO2003022801A1 (en)	2003-03-20	Reverse hydroxamic acid derivatives
WO2007033039A3 (en)	2007-10-04	Proteasome inhibiting beta lactam compounds
IL161843A (en)	2011-08-31	Derivatives of 2-amino-4-pyridylmethyl-thiazoline for the preparation of medicaments for use as inhibitors of inducible no-synthase

Legal Events

Date	Code	Title	Description
2003-03-13	AK	Designated states	Kind code of ref document: A1 Designated state(s): CN KR US Kind code of ref document: A1 Designated state(s): CN KR
2003-03-13	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
2003-05-07	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-02-06	WWE	Wipo information: entry into national phase	Ref document number: 1020047001888 Country of ref document: KR
2004-02-23	WWE	Wipo information: entry into national phase	Ref document number: 10487411 Country of ref document: US
2004-03-01	WWE	Wipo information: entry into national phase	Ref document number: 20028171039 Country of ref document: CN
2004-03-12	WWE	Wipo information: entry into national phase	Ref document number: 2002772819 Country of ref document: EP
2004-05-26	WWP	Wipo information: published in national office	Ref document number: 2002772819 Country of ref document: EP
2007-12-19	WWG	Wipo information: grant in national office	Ref document number: 2002772819 Country of ref document: EP